Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer stage IV melanoma: Results of the EORTC 18951 biochemotherapy trial

Journal of Clinical Oncology

Volumn 25, Issue 12, 2007, Pages 1562-1569

  Schmidt, Henrik ^a   Suciu, Stefan ^a   Punt, Cornells J A ^a   Gore, Martin ^a   Kruit, Wim ^a   Patel, Poulam ^a   Lienard, Danielle ^a   Von Der Maase, Hans ^a   Eggermont, Alexander M M ^a   Keilholz, Ulrich ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CISPLATIN; DACARBAZINE; LACTATE DEHYDROGENASE; RECOMBINANT INTERLEUKIN 2; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CANCER STAGING; CANCER SURVIVAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEALTH CARE ORGANIZATION; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; MULTIPLE CYCLE TREATMENT; NEUTROPHIL COUNT; PRIORITY JOURNAL; PROGNOSIS; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG ADMINISTRATION; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; NEUTROPHIL; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PREDICTION AND FORECASTING; PROBABILITY; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; REFERENCE VALUE; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SKIN TUMOR; SURVIVAL; UNITED STATES;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LEUKOCYTE COUNT; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; NEUTROPHILS; PREDICTIVE VALUE OF TESTS; PROBABILITY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REFERENCE VALUES; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SKIN NEOPLASMS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; UNITED STATES;

EID: 34248218014     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.09.0274     Document Type: Article

References (27)

1. Barth A, Wanek LA, Morton DL: Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll Surg 181:193-201, 1995
2. Atkins MB, Kunkel L, Sznol M, et al: High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: Long-term survival update. Cancer J Sci Am 6:S11-S14, 2000 (suppl 1)
3. Rosenberg SA, Yang JC, White DE, et al: Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: Identification of the antigens mediating response. Ann Surg 228:307-319, 1998
4. Manola J, Atkins M, Ibrahim J, et al: Prognostic factors in metastatic melanoma: A pooled analysis of Eastern Cooperative Oncology Group trials. J Clin Oncol 18:3782-3793, 2000
5. Eton O, Legha SS, Moon TE, et al: Prognostic factors for survival of patients treated systemically for disseminated melanoma. J Clin Oncol 16:1103-1111, 1998
6. Keilholz U, Conradt C, Legha SS, et al: Results of interleukin-2-based treatment in advanced melanoma: A case record-based analysis of 631 patients. J Clin Oncol 16:2921-2929, 1998
7. Keilholz U, Martus P, Punt CJ, et al: Prognostic factors for survival and factors associated with long-term remission in patients with advanced melanoma receiving cytokine-based treatments: Second analysis of a randomised EORTC Melanoma Group trial comparing interferon-alpha2a (IFNalpha) and interleukin 2 (IL-2) with or without cisplatin. Eur J Cancer 38:1501-1511, 2002
8. Balch CM, Buzaid AC, Soong SJ, et al: Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19:3635-3648, 2001
9. Mocellin S, Keilholz U, Rossi CR, et al: Circulating tumor cells: The 'leukemic phase' of solid cancers. Trends Mol Med 12:130-139, 2006
10. Hsueh EC, Gupta RK, Qi K, et al: TA90 immune complex predicts survival following surgery and adjuvant vaccine immunotherapy for stage IV melanoma. Cancer J Sci Am 3:364-370, 1997
11. Schmidt H, Johansen JS, Sjoegren P, et al: Serum YKL-40 predicts relapse-free and overall survival in patients with American Joint Committee on Cancer stage I and II melanoma. J Clin Oncol 24:798-804, 2006
12. Schmidt H, Johansen JS, Gehl J, et al: Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma. Cancer 106:1130-1139, 2006
13. Schmidt H, Bastholt L, Geertsen P, et al: Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: A prognostic model. Br J Cancer 93:273-278, 2005
14. Keilholz U, Punt CJ, Gore M, et al: Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: A randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol 23:6747-6755, 2005
15. Riesco A: Five-year cancer cure: Relation to total amount of peripheral lymphocytes and neutrophils. Cancer 25:135-140, 1970
16. Atzpodien J, Royston P, Wandert T, et al: Metastatic renal carcinoma comprehensive prognostic system. Br J Cancer 88:348-353, 2003
17. Negrier S, Escudier B, Gomez F, et al: Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: A report from the Groupe Francais d'Immunotherapie. Ann Oncol 13:1460-1468, 2002
18. Donskov F, von der Maase H: Impact of immune parameters on long-term survival in metastatic renal cell carcinoma. J Clin Oncol 24:1997-2005, 2006
19. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 100:57-70, 2000
20. Coussens LM, Werb Z: Inflammation and cancer. Nature 420:860-867, 2002
21. Balkwill F, Mantovani A: Inflammation and cancer: Back to Virchow? Lancet 357:539-545, 2001
22. Bingle L, Brown NJ, Lewis CE: The role of tumour-associated macrophages in tumour progression: Implications for new anticancer therapies. J Pathol 196:254-265, 2002
23. Mantovani A, Sica A, Locati M: Macrophage polarization comes of age. Immunity 23:344-346, 2005
24. Sica A, Schioppa T, Mantovani A, et al: Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: Potential targets of anti-cancer therapy. Eur J Cancer 42:717-727, 2006
25. Porcheray F, Viaud S, Rimaniol AC, et al: Macrophage activation switching: An asset for the resolution of inflammation. Clin Exp Immunol 142: 481-489, 2005
26. Lewis CE, Pollard JW: Distinct role of macrophages in different tumor microenvironments. Cancer Res 66:605-612, 2006
27. Dvorak HF: Tumors: Wounds that do not heal: Similarities between tumor stroma generation and wound healing. N Engl J Med 315:1650-1659, 1986